Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 3;14:8. doi: 10.1038/s41467-022-35431-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Volcano plot showing differentially expressed genes between baseline MPR (n = 2) vs. non-MPR (n = 10) group. Color dots denote genes that passed the p-value and fold change thresholds. b Functional pathway enrichment by differential expressed genes at baseline. Similar pathways are clustered and stained with the same colors. c Heatmap for immune-related gene expression across samples in 15 patients. d Baseline levels of immune-related genes that were altered between PPR+ (n = 3) and non-PPR+ (n = 9) groups. e Level changes of immune-related genes between pre- (n = 3) and post-treatment (n = 4) PPR+ patients. f Heatmap for immune-related signatures across samples in 15 patients. g Baseline levels of immune-related signatures that were altered between PPR+ (n = 3) and non-PPR+ (n = 9) groups. h Changes in immune-related signatures between pre- (n = 3) and post-treatment (n = 4) patients. Centers, boxes, and whiskers indicate medians, quantiles, and minima/maxima, respectively, in d-e and g-h. Two-sided Wilcoxon rank-sum test was used for comparison in d-e and g-h. Source data are provided as a Source Data file.